Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.243
Filter
1.
Photodermatol Photoimmunol Photomed ; 40(4): e12978, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38845020

ABSTRACT

BACKGROUND: Infections are complications in the wound healing process, and their treatment can lead to antibiotic overuse and bacterial resistance. Antimicrobial photodynamic therapy (aPDT) is used to treat infectious diseases caused by fungi, viruses, or bacteria. Methylene blue (MB) and its derivatives are commonly used dyes in antimicrobial photodynamic therapy (aPDT-MB). METHODS: This study is a PRISMA systematic review of animal models used to discuss the usefulness and therapeutic parameters of aPDT-MB or its derivatives for treating infected skin wounds. RESULTS: After an extensive literature review, 13 controlled trials totaling 261 animals were selected to evaluate skin infection by leishmaniasis and cutaneous bacterial and fungal infections. All studies found results favoring the use of aPDT-MB. Great variability in parameters was found for radiant exposure from 12 to 360 J/cm2, MB diluted in saline solution or distilled water, irradiation time from 40 to 3600 s, irradiance most commonly at a maximum of 100 mW/cm2, and wavelength used mainly in the 630-670 nm range. CONCLUSION: MB is a safe and promising agent used as a photosensitizer in aPDT for skin-infected lesions. There is great variability in the parameters found. Comparisons concerning concentration, irradiation time, and light intensity need to be performed.


Subject(s)
Methylene Blue , Photochemotherapy , Photosensitizing Agents , Animals , Disease Models, Animal , Methylene Blue/pharmacology , Methylene Blue/therapeutic use , Photochemotherapy/methods , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use
2.
Arch Oral Biol ; 164: 105978, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38718465

ABSTRACT

OBJECTIVE: To evaluate the effect of the association of potassium iodide to antimicrobial photodynamic therapy on human carious dentin produced with a microcosm biofilm model. METHODS: A microcosm biofilm model was used to generate a caries lesion on human dentin. Pooled human saliva diluted with glycerol was used as an inoculum on specimens immersed on McBain artificial saliva enriched with 1 % sucrose (24 h at 37 °C in 5 % CO2). After refreshing culture media for 7 days, the dentin specimens were divided in 5 groups (3 specimens per group, in triplicate; n = 9): C (NaCl 0.9 %), CX (2 % chlorhexidine), PKI (0.01 % methylene blue photosensitizer+50 mM KI), L (laser at 15 J, 180 s, 22.7 J/cm2), and PKIL (methylene blue + KI + Laser). After the treatments, dentin was collected, and a 10-fold serial dilution was performed. The number of total microorganisms, total lactobacilli, total streptococci, and Streptococcus mutans was analyzed by microbial counts (CFU/mL). After normality and homoscedasticity analysis, the Welch's ANOVA and Dunnett's tests were used for CFU. All tests used a 5 % significance level. RESULTS: CX and PKIL groups showed significant bacterial decontamination of dentin, compared to group C (p < 0.05) reaching reductions up to 3.8 log10 for CX for all microorganisms' groups and PKIL showed 0.93, 1.30, 1.45, and 1.22 log10 for total microorganisms, total lactobacilli, total streptococci, and S. mutans, respectively. CONCLUSION: aPDT mediated by the association of KI and methylene blue with red laser reduced the viability of microorganisms from carious dentin and could be a promising option for cavity decontamination.


Subject(s)
Biofilms , Dental Caries , Dentin , Methylene Blue , Photochemotherapy , Photosensitizing Agents , Potassium Iodide , Streptococcus mutans , Humans , Methylene Blue/pharmacology , Methylene Blue/therapeutic use , Photochemotherapy/methods , Dental Caries/microbiology , Dental Caries/drug therapy , Dental Caries/therapy , Dentin/microbiology , Dentin/drug effects , Potassium Iodide/pharmacology , Potassium Iodide/therapeutic use , Biofilms/drug effects , Streptococcus mutans/drug effects , Photosensitizing Agents/therapeutic use , Photosensitizing Agents/pharmacology , Saliva/microbiology , Lactobacillus/drug effects , Streptococcus/drug effects , Chlorhexidine/pharmacology , Chlorhexidine/therapeutic use , In Vitro Techniques , Colony Count, Microbial , Saliva, Artificial , Lasers
3.
BMJ Case Rep ; 17(5)2024 May 28.
Article in English | MEDLINE | ID: mdl-38806397

ABSTRACT

We present a case of a man in his late 40s presenting with generalised tonic-clonic seizures and profound methaemoglobinaemia shortly after inadvertent ingestion of amyl nitrite. Arterial blood gas analysis demonstrated methaemoglobin levels exceeding the upper detection threshold of our analyser, accompanied with profound cyanosis despite apparent oxygen saturations of 94%. Prompt administration of intravenous methylene blue led to a rapid and complete recovery. This case highlights the importance of swift recognition and treatment of methaemoglobinaemia particularly when the precipitating factor may be unknown at the time of presentation. This case also demonstrates the potential limitations of bedside blood gas analysers in diagnosis.


Subject(s)
Amyl Nitrite , Methemoglobinemia , Methylene Blue , Seizures , Humans , Methemoglobinemia/chemically induced , Methemoglobinemia/diagnosis , Male , Amyl Nitrite/poisoning , Amyl Nitrite/adverse effects , Methylene Blue/therapeutic use , Seizures/chemically induced , Adult , Blood Gas Analysis
4.
J Appl Oral Sci ; 32: e20230447, 2024.
Article in English | MEDLINE | ID: mdl-38695448

ABSTRACT

OBJECTIVE: To evaluate whether antimicrobial photodynamic therapy (aPDT) repairs bisphosphonate-related osteonecrosis of the jaw (BRONJ) modulated by the reduction of NF-kB protein in a murine model. METHODOLOGY: Male Wistar rats (N=30) were divided into the following groups (n=6/group): negative control (NC); experimental osteonecrosis (ONE); ONE + photosensitizer (PS); ONE + photobiomodulation (PBM); and ONE + aPDT. Over 8 weeks, ONE was induced by zoledronic acid 250 µg/kg injections, except in the NC group, which received sterile 0.9% saline, followed by extraction of the lower left first molar. Red light laser irradiation (wavelength ~660 nm, power 50 mW, energy of 2 J, energy dose of 66.67 J/cm2 for 40 s) was performed once a week for 4 weeks. Methylene blue 0.3% was used as PS. The animals were euthanized and examined macroscopically for the presence of exposed bone and epithelial repair and microscopically by histochemical (hematoxylin-eosin and Masson's trichrome staining) and immunohistochemical (anti-NF-kB) methods. Macroscopic and histomorphometric data were analyzed by one-way ANOVA and Tukey's post-test (p<0.05). RESULTS: Mucosal repair, viable osteocytes, and NF-kB immunostaining were observed in the NC, ONE+PS, ONE+PBM, and ONE+aPDT groups. The ONE group showed no mucosal repair, showing empty lacunae and multifocal immunostaining for NF-kB. The ONE+PBM and ONE+aPDT groups had greater deposition of extracellular matrix and less necrotic bone tissue (p<0.05). CONCLUSION: PBM and aPDT treatments for BRONJ were effective for bone and epithelial repair, in addition to reducing inflammation mediated by the decrease of NF-kB protein in the irradiated regions.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw , Disease Models, Animal , Immunohistochemistry , NF-kappa B , Photochemotherapy , Photosensitizing Agents , Rats, Wistar , Animals , Male , Photochemotherapy/methods , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , NF-kappa B/analysis , Photosensitizing Agents/pharmacology , Time Factors , Reproducibility of Results , Zoledronic Acid/pharmacology , Treatment Outcome , Imidazoles/pharmacology , Diphosphonates/pharmacology , Low-Level Light Therapy/methods , Methylene Blue/pharmacology , Methylene Blue/therapeutic use , Analysis of Variance , Random Allocation , Bone Density Conservation Agents/pharmacology
5.
Am J Emerg Med ; 81: 159.e1-159.e5, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38627127

ABSTRACT

INTRODUCTION: Methemoglobinemia, characterized by the conversion of functional hemoglobin to methemoglobin, can significantly impede tissue oxygenation. Prompt diagnosis and treatment of methemoglobinemia are critical to optimizing clinical outcomes. Although the underlying etiology of methemoglobinemia is often attributed to a medication reaction or chemical exposure, its association with battlefield trauma remains underexplored. This case series explores the presence of methemoglobinemia in nine soldiers evacuated from tanks targeted by explosives, shedding new light on screening needs and treatment strategies. CASES DESCRIPTION: Nine combat trauma patients with methemoglobinemia were admitted to Soroka Medical Center over a two-month period. Detailed case descriptions illustrate the diverse presentations and treatment responses. Notably, the administration of methylene blue resulted in rapid methemoglobin reductions and an improvement in oxygenation without any observed side effects. DISCUSSION: This series highlights an unexpected consequence of an explosion within an armored fighting vehicle and the challenges related to standard pulse oximetry interpretation and accuracy in the presence of methemoglobinemia, emphasizing the need for vigilant monitoring and co-oximetry utilization. Additionally, the coexistence of carboxyhemoglobin further warrants attention due to its synergistic and deleterious effects on oxygen delivery. Collaborative efforts with military authorities should aim to explore the underlying mechanisms associated with trauma and methemoglobinemia and optimize battlefield care. CONCLUSION: This case series underscores the significance of methemoglobinemia screening in combat trauma patients, and advocates for systematic co-oximetry utilization and methylene blue availability in combat zones. Early detection and intervention of methemoglobinemia in combat soldiers are often difficult in the context of battlefield injuries but are necessary to mitigate the potentially fatal consequences of this condition.


Subject(s)
Methemoglobinemia , Methylene Blue , Humans , Methemoglobinemia/chemically induced , Methemoglobinemia/diagnosis , Male , Methylene Blue/therapeutic use , Adult , Military Personnel , Oximetry , Young Adult , Blast Injuries/complications , Mass Screening/methods
6.
Braz J Cardiovasc Surg ; 39(3): e20230066, 2024 Apr 03.
Article in English | MEDLINE | ID: mdl-38569061

ABSTRACT

Microvasculature failure is expected in sepsis and at higher amine concentrations. Therefore, special attention focused individually on microcirculation is needed. Here, we present that methylene blue can prevent leukocytes from adhering to the endothelium in a rat model of lipopolysaccharide-induced endotoxemia. As hypothesis evidence, an intravital microscopy image is presented.


Subject(s)
Sepsis , Vasoplegia , Rats , Animals , Methylene Blue/pharmacology , Methylene Blue/therapeutic use , Vasoconstrictor Agents , Vasoplegia/drug therapy , Sepsis/drug therapy , Intravital Microscopy
8.
J Neonatal Perinatal Med ; 17(2): 261-264, 2024.
Article in English | MEDLINE | ID: mdl-38640175

ABSTRACT

 Cyanosis is a bluish discoloration of the tissues due to increased levels of deoxygenated hemoglobin in capillaries. It is a common finding in newborn infants that can be caused by different diseases, including pulmonary, cardiac, infectious, and hematological disorders. Methemoglobinemia is a rare cause of cyanosis, in which hemoglobin is oxidized, changing its heme iron configuration from the ferrous (Fe2 +) to the ferric (Fe3 +) state, creating methemoglobin (Met-Hb), a form that does not bind oxygen, leading to decreased oxygen delivery to the tissues and cyanosis. We report a rare case of a preterm newborn, who developed cyanosis and worsening hypoxemia on day ten of life, she was found to have elevated Met-Hb percentage in blood gas analysis that required treatment with intravenous methylene blue. Her symptoms resolved after a period of maintenance treatment with oral methylene blue and ascorbic acid, and the etiology of her disease remains unclear.


Subject(s)
Ascorbic Acid , Cyanosis , Infant, Premature , Methemoglobinemia , Methylene Blue , Humans , Methemoglobinemia/diagnosis , Methemoglobinemia/etiology , Infant, Newborn , Female , Methylene Blue/therapeutic use , Cyanosis/etiology , Ascorbic Acid/therapeutic use , Ascorbic Acid/administration & dosage , Blood Gas Analysis , Hypoxia/etiology
9.
Photodiagnosis Photodyn Ther ; 46: 104050, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38548040

ABSTRACT

OBJECTIVE: The aim was to systematically review clinical studies that investigated the efficacy of antimicrobial photodynamic therapy (aPDT) in reducing oral yeasts growth (OYG) in individuals wearing implant overdentures (IO). METHODS: The focused question was "Is aPDT effective in reducing OYG in patients wearing IO?" Literature search was performed in accordance with PRISMA guidelines. Indexed databases were searched without time and language restrictions up to and including January 2024. Clinical studies were included; and letters to the Editor, case-reports/case-series, perspectives/commentaries, in-vitro/ex-vivo studies, studies on animal models and expert opinions were excluded. The risk of bias was also assessed. RESULTS: Two clinical studies were included and processed for data extraction. The study population comprised of 100 (mean age: 58.5 years) and 53 (mean age: 58.5 years) individuals. The numbers of males and females included in these studies ranged between 33 and 35 males and 18-67 females, respectively. In both studies, follow-up evaluations were performed after 60 days. In both studies, aPDT was performed using a 660 nm diode laser at a power of 100 mW and using methylene-blue as photosensitizer. Results from both studies showed that aPDT is effective in significantly reducing oral yeasts CFU/ml and improvement of OHRQoL of individuals using IO. CONCLUSION: The aPDT is useful in reducing OYG on IO; however, further well-designed and power-adjusted studies are needed in this area of research.


Subject(s)
Denture, Overlay , Photochemotherapy , Photosensitizing Agents , Photochemotherapy/methods , Humans , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use , Methylene Blue/pharmacology , Methylene Blue/therapeutic use , Lasers, Semiconductor/therapeutic use , Yeasts/drug effects , Clinical Trials as Topic
10.
Clin Transplant ; 38(3): e15271, 2024 03.
Article in English | MEDLINE | ID: mdl-38485687

ABSTRACT

INTRODUCTION: For patients with catecholamine-resistant vasoplegic syndrome (VS) during liver transplantation (LT), treatment with methylene blue (MB) and/or hydroxocobalamin (B12) has been an acceptable therapy. However, data on the effectiveness of B12 is limited to case reports and case series. METHODS: We retrospectively reviewed records of patients undergoing LT from January 2016 through March 2022. We identified patients with VS treated with vasopressors and MB, and abstracted hemodynamic parameters, vasopressor requirements, and B12 administration from the records. The primary aim was to describe the treatment efficacy of B12 for VS refractory to vasopressors and MB, measured as no vasopressor requirement at the conclusion of the surgery. RESULTS: One hundred one patients received intraoperative VS treatment. For the 35 (34.7%) patients with successful VS treatment, 14 received MB only and 21 received both MB and B12. Of the 21 patients with VS resolution after receiving both MB and B12, 17 (89.5%) showed immediate, but transient, hemodynamic improvements at the time of MB administration and later showed sustained response to B12. CONCLUSION: Immediate but transient hemodynamic response to MB in VS patients during LT supports the diagnosis of VS and should prompt B12 administration for sustained treatment response.


Subject(s)
Liver Transplantation , Vasoplegia , Humans , Methylene Blue/therapeutic use , Hydroxocobalamin/therapeutic use , Vasoplegia/drug therapy , Vasoplegia/etiology , Retrospective Studies , Liver Transplantation/adverse effects , Vasoconstrictor Agents
12.
Photodiagnosis Photodyn Ther ; 46: 104000, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38316339

ABSTRACT

OBJECTIVE: This study aimed to assess the influence of methylene blue (MB)-mediated adjunctive antimicrobial photodynamic therapy (aPDT) when compared to conventional mechanical debridement (MD) alone on periodontal clinical and radiographic outcomes among periodontitis patients. METHODS: Randomized clinical trials (RCTs) were incorporated by conducting an electronic search in Web of Science, Scopus, and PubMed for articles published in English up to August 2023 to address the following focused question based on the PICO format: "Whether the application of MB-mediated aPDT as an adjunctive to MD (Intervention) leads to improved periodontal clinical and/or radiographic outcomes (Outcome) among participants with and without periodontal diseases (Population) as compared to MD alone (Conparison)". The risk of bias (RoB) of the included studies was assessed using the modified Jadad scale. A meta-analysis was conducted, and it included the presentation of the standard mean difference (SMD) along with a 95 % confidence interval (CI). RESULTS: In total, 11 studies were included in this systematic review and meta-analysis. The meta-analysis demonstrated statistically significant improvements in periodontal plaque index (SMD: -0.72 % [95 % CI: -0.99 % to -0.45 %]; p<0.00001), probing depth (SMD: -0.38 % [95 % CI: -0.57 % to -0.19 %; p<0.00001), and bleeding on probing (SMD: -0.44 % [95 % CI: -0.68 % to -0.20 %]; p = 0.0003) scores at the final follow-up visit after the application of MB-mediated aPDT in comparison with MD alone. Nevertheless, there was no statistically significant difference was observed in periodontal clinical attachment level values (SMD: -0.01 % [95 % CI: -0.21 % to 0.19 %]; p = 0.95) between the control group and the experimental group. Six studies achieved a low RoB, five were rated as having medium RoB, while no study received a high RoB. CONCLUSION: MB-mediated aPDT, when used as an adjunct to conventional MD contributes to the improvement of periodontal clinical outcomes including PI, PD, and BOP in patients with periodontitis.


Subject(s)
Methylene Blue , Photochemotherapy , Photosensitizing Agents , Randomized Controlled Trials as Topic , Methylene Blue/therapeutic use , Humans , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Periodontal Diseases/drug therapy
13.
Surg Oncol ; 53: 102046, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38377643

ABSTRACT

PURPOSE: In patients with colorectal cancer (CRC), the most important factor to decide the need of adjuvant chemotherapy is the histological lymph node (LN) evaluation. Our work aimed to give a broad view over the use of methylene blue and its consequences in the number of lymph node harvest. METHODS: PUBMED, WEB OF SCIENCE and EMBASE databases were consulted, retrieving clinical trials, which mentioned the used of intra-arterial methylene blue in patients with colorectal cancer. RESULTS: Eighteen clinical trials analyzing the use of intra-arterial methylene blue in specimens of colorectal cancer were selected. The articles show a statistical difference between the use of methylene blue and the classical dissection in both variable at study. The results of the statistical analysis of the lymph node harvest variable demonstrate a significant statistical difference between the group that received methylene blue injection and the group that underwent conventional dissection. There is a significant statistical difference between the experimental and control groups for the ideal lymph node harvest (lymph node harvest count greater than 12). CONCLUSION: The use of intra-arterial methylene blue revealed a high potential for the quantification of lymph nodes, considering the increase of lymph node harvest and the higher percentage of cases with more than 12 lymph nodes count, albeit the high heterogeneity between the studies in terms of reported results. Future investigations with controlled double blinded studies obtaining better categorized results should be conducted in order to better evaluate this technique and compare it to the current paradigm.


Subject(s)
Colorectal Neoplasms , Lymph Node Excision , Humans , Lymph Node Excision/methods , Methylene Blue/therapeutic use , Lymph Nodes/pathology , Dissection , Colorectal Neoplasms/pathology , Sentinel Lymph Node Biopsy
14.
Adv Mater ; 36(19): e2307081, 2024 May.
Article in English | MEDLINE | ID: mdl-38395039

ABSTRACT

The accumulation of hyperphosphorylated tau protein aggregates is a key pathogenic event in Alzheimer's disease (AD) and induces mitochondrial dysfunction and reactive oxygen species overproduction. However, the treatment of AD remains challenging owning to the hindrance caused by the blood-brain barrier (BBB) and the complex pathology of AD. Nasal delivery represents an effective means of circumventing the BBB and delivering drugs to the brain. In this study, black phosphorus (BP) is used as a drug carrier, as well as an antioxidant, and loaded with a tau aggregation inhibitor, methylene blue (MB), to obtain BP-MB. For intranasal (IN) delivery, a thermosensitive hydrogel is fabricated by cross-linking carboxymethyl chitosan and aldehyde Pluronic F127 (F127-CHO) micelles. The BP-MB nanocomposite is incorporated into the hydrogel to obtain BP-MB@Gel. BP-MB@Gel could be injected intranasally, providing high nasal mucosal retention and controlled drug release. After IN administration, BP-MB is continuously released and delivered to the brain, exerting synergistic therapeutic effects by suppressing tau neuropathology, restoring mitochondrial function, and alleviating neuroinflammation, thus inducing cognitive improvements in mouse models of AD. These findings highlight a potential strategy for brain-targeted drug delivery in the management of the complex pathologies of AD.


Subject(s)
Administration, Intranasal , Alzheimer Disease , Chitosan , Cognitive Dysfunction , Hydrogels , Methylene Blue , Methylene Blue/chemistry , Methylene Blue/therapeutic use , Methylene Blue/pharmacology , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Animals , Mice , Hydrogels/chemistry , Chitosan/chemistry , Chitosan/analogs & derivatives , Cognitive Dysfunction/drug therapy , Poloxamer/chemistry , Drug Carriers/chemistry , Brain/metabolism , Brain/drug effects , Brain/pathology , Micelles , tau Proteins/metabolism , Disease Models, Animal , Drug Liberation , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/drug effects , Nanocomposites/chemistry , Nanocomposites/therapeutic use , Mitochondria/metabolism , Mitochondria/drug effects
15.
BMJ Open ; 14(1): e080065, 2024 01 12.
Article in English | MEDLINE | ID: mdl-38216185

ABSTRACT

OBJECTIVE: This meta-analysis aimed to demonstrate the effect of methylene blue (MB) in patients with distributive shock. DESIGN: Meta-analysis. METHODS: According to the Prospective International Register of Systematic Reviews (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched the relevant randomised controlled trials (RCTs) via PubMed, Embase and Cochrane Library from the date of database inception to 19 April 2023. The primary outcome was mortality during follow-up, and secondary outcomes included mean arterial pressure (mm Hg), mechanical ventilation time (hours), intensive care unit (ICU) length of stay (LOS) (days), hospital LOS (days) and heart rate (times/min). RESULTS: This study included six RCTs with 265 participants. The study showed no significant difference in mortality between the MB and placebo groups (ORs: 0.59; 95% CI 0.32 to -1.06). However, MB reduced the duration of mechanical ventilation (mean difference (MD): -0.68; 95% CI -1.23 to -0.14), ICU LOS (MD: -1.54; 95% CI -2.61 to -0.48) and hospital LOS (MD: -1.97; 95% CI -3.92 to -0.11). CONCLUSIONS: The use of MB may not reduce mortality in patients with distributive shock, but may shorten the duration of mechanical ventilation, ICU LOS and hospital LOS. More clinical studies are needed to confirm these findings in the future. TRIAL REGISTRATION NUMBER: CRD42023415938.


Subject(s)
Methylene Blue , Respiration, Artificial , Humans , Hospital Mortality , Intensive Care Units , Length of Stay , Methylene Blue/therapeutic use , Randomized Controlled Trials as Topic , Shock/mortality
16.
J Biophotonics ; 17(4): e202300412, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38253349

ABSTRACT

This study aimed to evaluate the clinical evolution of patients with diabetic foot ulcer treated with antimicrobial photodynamic therapy (aPDT) using the Bates-Jensen (BJ) scale. A total of 21 patients were monitored, with an average age of 58 years. Patients underwent the standard treatment protocol of the institution, supplemented with aPDT utilizing 0.01% methylene blue (MB) and laser irradiation (660 nm, 100 mW, 6 J per point). Following aPDT, the lesions were protected with hydrofiber dressings containing silver. The Bates-Jensen Scale was employed at pre-treatment and post-aPDT sessions to assess lesion progression. The results demonstrated a significant difference between pre- and post-treatment values in the overall BJ score. The use of MB in aPDT proved to be an effective, safe, well-tolerated treatment with high patient adherence and the potential for implementation in the care of diabetic foot conditions.


Subject(s)
Anti-Infective Agents , Diabetes Mellitus , Diabetic Foot , Photochemotherapy , Humans , Middle Aged , Photosensitizing Agents/therapeutic use , Diabetic Foot/drug therapy , Photochemotherapy/methods , Treatment Outcome , Methylene Blue/pharmacology , Methylene Blue/therapeutic use
17.
Biomed Mater ; 19(2)2024 Jan 19.
Article in English | MEDLINE | ID: mdl-38181448

ABSTRACT

Antimicrobial wound dressings play a crucial role in treatment of wound infections. However, existing commercial options fall short due to antibiotic resistance and the limited spectrum of activity of newly emerging antimicrobials against bacteria that are frequently encountered in wound infections. Antimicrobial photodynamic therapy (aPDT) is very promising alternative therapeutic approach against antibiotic resistant microbes such as methicillin resistantStaphylococcus aureus (MRSA). However, delivery of the photosensitizer (PS) homogeneously to the wound site is a challenge. Though polymeric wound dressings based on synthetic and biopolymers are being explored for aPDT, there is paucity of data regarding theirin vivoefficacy. Moreover, there are no studies on use of PS loaded, pluoronic (PL) and pectin (PC) based films for aPDT. We report development of a polymeric film for potential use in aPDT. The film was prepared using PL and PC via solvent casting approach and impregnated with methylene blue (MB) for photodynamic inactivation of MRSAin vitroandin vivo. Atomic force microscopic imaging of the films yielded vivid pictures of surface topography, with rough surfaces, pores, and furrows. The PL:PC ratio (2:3) was optimized that would result in an intact film but exhibit rapid release of MB in time scale suitable for aPDT. The film showed good antibacterial activity against planktonic suspension, biofilm of MRSA upon exposure to red light. Investigations on MRSA infected excisional wounds of mice reveal that topical application of MB loaded film for 30 min followed by red light exposure for 5 min (fluence; ∼30 J cm-2) or 10 min (fluence; ∼60 J cm-2) reduces ∼80% or ∼92% of bioburden, respectively. Importantly, the film elicits no significant cytotoxicity against keratinocytes and human adipose derived mesenchymal stem cells. Taken together, our data demonstrate that PS-loaded PL-PC based films are a promising new tool for treatment of MRSA infected wounds.


Subject(s)
Anti-Infective Agents , Methicillin-Resistant Staphylococcus aureus , Wound Infection , Animals , Mice , Humans , Methicillin/therapeutic use , Poloxamer/therapeutic use , Methylene Blue/therapeutic use , Pectins/therapeutic use , Photosensitizing Agents , Anti-Bacterial Agents , Polymers , Biofilms , Wound Infection/drug therapy , Wound Infection/microbiology
19.
J Cardiothorac Vasc Anesth ; 38(1): 268-274, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37880041

ABSTRACT

Vasodilatory hypotension is common in critically ill and perioperative patients, and is associated with adverse outcomes. As a nitric oxide production inhibitor, methylene blue (MB) exerts its vasoconstrictor property and is an adjuvant for catecholamine-refractory vasodilatory shock. However, the effects of MB on clinically relevant outcomes remain unclear. Therefore, the authors performed a meta-analysis of randomized trials on MB in critically ill and perioperative patients. The authors searched through databases for randomized trials on MB in critically ill and perioperative patients, which yielded 11 studies consisting of 556 patients. The primary outcome was mortality at the longest follow-up. Secondary outcomes included hemodynamic parameters and organ dysfunction (PROSPERO: CRD42023409243). Nine out of the 11 included randomized trials reported mortality, which was significantly lower in the MB group (risk ratio, 0.60 [95% CI 0.43-0.84] p = 0.003), with findings confirmed in septic shock and cardiac surgery subgroups. The authors found reduced lengths of stay in the intensive care unit (mean difference [MD], -0.9 days [95% CI -1.06 to -0.77] p < 0.001) and in the hospital (MD, -2.2 days [95% CI, -2.68 to -1.70] p < 0.001) in the MB group. MB was associated with increased mean arterial pressure (MD, 8.4 mmHg [95% CI 5.01-11.75] p < 0.001) and systemic vascular resistance (MD, 94.5 dyn/s/cm5 [95% CI 17.73-171.15] p = 0.02), with no difference in cardiac output (standardized MD, 0.16 [95% CI, -0.25 to 0.57] p = 0.45). This meta-analysis showed that MB reverses vasodilation in critically ill and perioperative patients and might improve survival. Further adequately powered randomized trials are needed to confirm these findings.


Subject(s)
Hypotension , Shock, Septic , Shock , Humans , Methylene Blue/therapeutic use , Critical Illness/therapy , Randomized Controlled Trials as Topic , Shock, Septic/drug therapy
20.
Mycoses ; 67(1): e13661, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37840157

ABSTRACT

BACKGROUND: Methylene blue (MB) and flavin mononucleotide (FMN)-mediated photodynamic therapy (PDT) have demonstrated local antimicrobial effect, but no direct comparative study has been published so far for the treatment of toenail onychomycosis. OBJECTIVES: To directly compare the short and medium-term efficacy of MB versus FMN as photosensitizers in PDT for toenail onychomycosis by applying them in a 40% w/w urea cream in two different dye concentrations. METHODS: Forty toenails with distal and lateral subungual moderate onychomycosis due to dermatophyte fungi were randomised to receive 10 weekly sessions of PDT mediated by four topical formulations including MB or FMN at two different concentrations: Group I: 0.1% w/w MB; Group II: 2% w/w MB; Group III: 0.1% w/w FMN; and Group IV: 2% w/w FMN. Photographs were used for onychomycosis severity index (OSI) estimation allowing clinical assessment at any point of the study. Microscopic and microbiological evaluations were carried out at baseline, 27- and 35-week follow-ups. Side effects were recorded along with patient satisfaction. RESULTS: At week 27, mycological cure rates were 60%, 30%, 50% and 40% and complete cure rates were 0%, 20%, 10% and 20%, for Groups I, II, III and IV respectively. At week 35, mycological cure rates were 70%, 70%, 70% and 60% and complete cure rates were 30%, 50%, 70% and 30%, for Groups I, II, III and IV respectively. All cream formulations were safe and patients were fairly satisfied. CONCLUSIONS: Results of the present work confirm PDT as a therapeutic alternative for onychomycosis. Although all cream formulations were safe and effective, with a good degree of satisfaction, higher cure rates were obtained with 2% w/w MB cream and 0.1% w/w FMN cream.


Subject(s)
Foot Dermatoses , Onychomycosis , Humans , Antifungal Agents/therapeutic use , Onychomycosis/drug therapy , Nails , Methylene Blue/therapeutic use , Flavin Mononucleotide/therapeutic use , Foot Dermatoses/drug therapy , Urea , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...